Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck. A phase II trial

Phase I Trial of Radiochemotherapy with Bendamustine in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck

“…On the other hand, randomized studies have demonstrated the superiority of radiotherapy in combination with chemotherapy over radiotherapy alone. RCT with multiagent chemotherapy, or with hyperfractionated radiotherapy, may lead to even better outcomes, although toxicity may be increased [2,3,8,11,14,15,17,18,20,22,25,32].…”

Perspectives on cancer therapy-induced mucosal injury

“…The incidence of oral and GI mucositis varied significantly among different treatment regimens and modalities (Table 4). 60–398 Most anthracycline‐based regimens were associated with rates of oral mucositis in the 1–10% range, except when regimens included 5‐FU. Included among these are the standard regimens for adjuvant therapy in patients with breast cancer (5‐FU, doxorubicin, and cyclophosphamide; doxorubicin and cyclophosphamide; or 5‐FU, epirubicin, and cyclophosphamide) as well as regimens for patients with non‐Hodgkin lymphomas, including cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP).…”

3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing

“…incorporating modern chemotherapy schedules. In highly aggressive simultaneous chemoradiation regimen dose limiting acute mucositis grade 3 and 4 occur in up to 80% of patients [ 18 ]. Therefore 3D-c-IMRT with its low volume of heavily irradiated mucosa and large proportion of mucosa irradiated with low daily doses of 1.6–1.75 Gy seems an ideal technology to be combined with aggressive multidrug chemotherapy protocols.…”